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Aim. The aim of this study is to present the oncologic outcomes and to determine the prognostic factors of overall survival (OS),
cancer-speciﬁc survival (CSS), disease-progression-free survival (DPFS), and biochemical-progression-free survival (BPFS) after
surgery for pT3 prostate cancer (PCa). Methods. Between 2002 and 2007, a pT3 stage after radical prostatectomy was detected in
182patientsatourinstitution.TheKaplan-MeieranalysiswasusedtocalculateOS,CSS,DPFS,andBPFS.Coxregressionwasused
to identify predictive factors of survival. Results. pT3a was detected in 126 (69%) and pT3b in 56 (31%) of cases. Five-year OS,
CSS, DPFS, and BPFS rates were 90.7%, 94%, 91.8%, and 48.4%, respectively. Survival was signiﬁcantly diﬀerent when comparing
pT3a to pT3b groups. The 5-year OS, CSS, DPFS, and BPFS were 96% versus 72%, 98% versus 77%, 97.3% versus 79.3%, and
60% versus 24.2%, respectively. Specimen Gleason score was the most signiﬁcant predictor of OS, CSS, DPFS, and BPFS. The risk
of death increased up to 3-fold when a Gleason score 8–10 was present at the ﬁnal pathology. Conclusions. Radical prostatectomy
may oﬀer very good CSS, OS, DPFS, and BPFS rates in pT3a PCa. However, outcomes in patients with pT3b or specimen Gleason
≥8 were signiﬁcantly worse, suggesting the need for multimodality treatment in those cases.
1.Introduction
During the last decade, the deﬁnition of the optimal
treatment in high-risk prostate cancer (PCa) has been
among the topics that are of most interest to the urological
community, but consensus in this ﬁeld is still not reached.
Up until a decade ago, most T3 PCa patients underwent
radiotherapy (RT) or androgen deprivation therapy (ADT)
oracombinationofboth,whileonlyabout36%wereinitially
treatedbysurgery[1]. Recent publications have revealed that
inselectedcasesoflocallyadvancedandhigh-gradetumours,
surgery as monotherapy or as part of a multimodality
treatment may be used instead of RT [2]. The high-risk
PCa population, usually described as having prostate speciﬁc
antigen (PSA) >20ng/mL, biopsy Gleason score ≥8, or
an advanced clinical stage (T3a-b) [3], is however not
homogeneous. Recent studies have shown that treatment
outcomes can vary widely, depending on whether patients
present with only one or rather a combination of those
high-risk factors, with the latter patients having the worst
outcomes [4–7]. It is still unclear which patients, according
to the accepted predictors of aggressive disease behaviour,
are the best candidates for surgery, mostly due to the lack
of data on long-term oncologic outcomes and randomized
clinical trials. According to the European Association of
Urology guidelines, surgery is optional in patients presenting
with cT3a, Gleason score 8–10, or PSA >20ng/mL and life
expectancy of more than 10 years [8]. Even in highly selected
patients with cT3b or cN1 PCa, surgery may be oﬀered
as part of a multimodality approach [8]. We believe that
radical prostatectomy is indeed an appropriate treatment for
more aggressive PCa, but data for conﬁrming that are still
insuﬃcient.
The purpose of this study is to present the oncologic
outcomes of patients having pT3a and pT3b PCa after
surgery, including overall survival (OS), cancer-speciﬁc sur-
vival (CSS), disease-progression-free survival (DPFS), and
biochemical-progression-free survival (BPFS). Furthermore,
we aimed to analyze predictive parameters in survival.2 Advances in Urology
2.MaterialandMethods
During the period 2002–2007, 840 radical retropubic prosta-
tectomies (RRP) were performed in our tertiary referral
institution. 192 of them had pathological stage T3 (22.9%).
Ten patients were lost for additional followup. Final analysis
was carried out using the data of 182 patients with complete
followup. No patients received neoadjuvant treatment. The
last PSA before biopsy was used for analysis.
Biopsy Gleason score ≥7, PSA >10ng/mL, or clinical
stage T3 was indication for lymph node removal. 113 of 182
(62.1%) patients of our study population had such criteria.
For the other 69 (37.9%) patients, a lymphadenectomy was
not performed.
The pathological examination of radical prostatectomy
specimens and bilateral pelvic lymph nodes was performed
by one dedicated uropathologist.
Serum PSA and physical examination were performed
every 3 months in the ﬁrst year after surgery, every 6 months
in the second and third years, and annually thereafter. The
PSA data were taken from outpatient clinic ﬁles. Data about
patients’ death and cause of death were received from the
National Cancer Registry.
OS was deﬁned as the time from surgery to death from
any cause. CSS was deﬁned as the time from surgery to death
caused by PCa or complications of this disease. Biochemical
progressionwasdeﬁnedasthetimefromsurgerytoPSAlevel
≥0.2ng/mL conﬁrmed by repeated test. Disease progression
was deﬁned as the development of either local disease
recurrence or distant metastasis. Adjuvant treatment was
deﬁned as either ADT or RT given within 3 months after
surgery.Salvagetreatmentwasdeﬁnedasanykindoftherapy
(RT or ADT) given later than 3 months after surgery. The
main indication for adjuvant treatment was positive lymph
nodes. Combination of Gleason score ≥8, preoperative PSA
>20ng/mL, pT3b, and positive surgical margins were other
indicators for adjuvant treatment.
The Kaplan-Meier survival analysis was used to calculate
the OS, CSS, DPFS, and BPFS. The diﬀerences were tested
by log-rank test. The Cox regression analysis was used to
determine the prognostic factors for survival.
3. Results
An overview of the patients’ preoperative and postoperative
parameters is shown in Table 1. The median followup was
54 months (range 6–96). 5-year rates for OS, CSS, DPFS,
and BPFS in our study cohort were 90.7%, 94%, 91.8%,
and, 48.4%, respectively. Cox regression analysis revealed
that from all parameters (age, biopsy and surgery Gleason
score, surgical margin and lymph node status, pathological
stage, and preoperative PSA level) only pathological stage
and postoperative Gleason score had an impact on overall
mortality and disease progression (Table 2). The Gleason
score also has the strongest impact on CSS. According to
Cox regression analysis, there were no other parameters
inﬂuencing cancer speciﬁc mortality (Table 2). Pathological
stage, lymph node status and postoperative Gleason score
were the strongest prognostic factors for biochemical disease
progression (Table 2).
3.1. Lymph Node Status. A mean of 6.4 (range 1–15) lymph
nodes were removed, and the overall positive node detection
rate was 10.6%. During the study period, the overall
mortality rate in pN1 patients was 50% and cancer-speciﬁc
mortality rate was 33.3%. Patients with pN0 or pNx had
signiﬁcantlyloweroverall(6.9%and5.8%,resp.)andcancer-
speciﬁc mortality rate (5.0% and 2.9%, resp.). The Kaplan-
Meier analysis showed that 5-year OS (93% versus 40%,
Figure 1(a)), CSS (95% versus 50%, Figure 1(b)), and DPFS
(96.5% versus 92.6% versus 40.7%) rates were signiﬁcantly
diﬀerent when comparing pNx, pN0, and pN1, respectively.
There was no diﬀerence between pNx and pN0 in survival
analysis. PSA relapse rate was diﬀerent comparing patients
with pN1, pN0, and pNx. 5-year BPFS was 0% in pN1 group,
43.4% in pN0, and 65.3% in pNx groups (Figure 1(c)).
3.2. Pathological Stage. The Kaplan-Meier analysis showed
that pT3a and pT3b stages provide signiﬁcantly diﬀerent
5-year OS (96% versus 72%, resp.; Figure 2(a)), CSS (98%
versus 77%, resp.; Figure 2(b)), DPFS (97.3% versus 79.3%,
resp.) and BPFS (60% versus 24.2%, resp.; Figure 2(c)).
Positive lymph nodes were found signiﬁcantly less frequently
in pT3a (2 of 71, 2.8%) than pT3b PCa (10 of 42, 23.8%)
(P = 0.0001). Lymph node positivity did not impact survival
in the stage pT3a PCa, but had a signiﬁcant role in the stage
pT3b PCa. Estimated 5-year OS, CSS, and DPFS rates in
pT3bN1 (38%, 50%, and 38.6%, resp.) were signiﬁcantly
worse (P = 0.0001) compared with pT3bN0-Nx (84%, 88%,
and 86.2%, resp.). 5-year BPFS rate was 31% in patients with
pT3bN0-Nx while all patients with pT3bN1 had biochemical
relapse during the study period.
3.3. Gleason Score. During the study, close correlation
between pathological stage and cancer diﬀerentiation was
established. The mean biopsy Gleason score was signiﬁcantly
worse in pT3b compared to pT3a PCa (6.8 versus 6.4,
P = 0.001) and after surgery (7.5 versus 6.9, P = 0.001).
Gleason score upgrading was detected in 52.5% of cases
and downgrading in 5.6% of cases. Increased Gleason score
was correlated with an increased positive lymph node rate:
29.2% at Gleason ≥8v e r s u s5 . 7 %a tG l e a s o n≤7( P =
0.003). The Kaplan-Meier analysis demonstrates signiﬁcant
diﬀerencesbetween Gleason ≤7and≥8f o rOS(Figure 3(a)),
CSS (Figure 3(b)), DPFS, and BPFS (Figure 3(c)) in the total
study population. The estimated 5-year OS, CSS, DPFS, and
BPFSratesinpatientswithGleasonscore ≥8were61%,64%,
62.4%,and13.5%,respectively,whileinGleasonscore ≤7,5-
year OS, CSS, DPFS, and BPFS were 96%, 99%, 97.8%, and
56.3%, respectively.
3.4. Surgical Margin Status. Positive surgical margin (R1)
rate was signiﬁcantly diﬀerent (P = 0.03) comparing pT3a
to pT3b cases (Table 1). Although in Cox regression this
parameter was not determined as prognostic factor for
survival the Kaplan-Meier analysis demonstrated diﬀerent 5-
year CSS (98.6% versus 90%, log-rank P = 0.047) and BPFS
(55.9% versus 44.2%, log-rank P = 0.08) rates comparing
R0 to R1 in all study population. Impact of surgical margin
status on outcome was analyzed separately in patients whoAdvances in Urology 3
Table 1: Patient characteristics.
Parameter pT3a (N = 126, 69.2%) pT3b (N = 56, 30.8%) All (N = 182, 100%)
Median age (yr) (range) 66.5 (49–78) 65 (48–76) 66 (48–78)
Median PSA (ng/mL) (range) 7.63 (0.68–39.89) 11.6 (3.1–98.4) 8.67 (0.68–98.4)
Mean biopsy Gleason (range)
Gleason ≤6
Gleason 7
Gleason ≥8
6.4 (6–9)
68.3%
26.0%
5.7%
6.8 (5–10)
41.1%
41.1%
17.9%
6.5 (5–10)
59.8%
30.7%
9.5%
Mean surgery Gleason (range)
Gleason ≤6
Gleason 7
Gleason ≥8
6.9 (6–9)
19.8%
71.4%
8.8%
7.5 (6–9)
3.6%
58.2%
38.2%
7.1 (6–9)
14.9%
67.4%
17.7%
R (%) 54.2% 71.7% 59.5%
N+ (rate) 2.8% (2/71) 23.8% (10/42) 10.6% (12/113)
PSA relapse 29.6% 75.0% 43.6%
Deaths (rate) 3.2% (4/126) 23.2% (13/56) 9.3% (17/182)
Deaths from cancer (rate) 0.8% (1/126) 17.9% (10/56) 6% (11/182)
mts 2.4% 17.9% 7.1%
Median followup (mo) (range) 56 (7–96) 50.5 (6–94) 54 (6–96)
Table 2: Cox multivariate regression analysis of preoperative and histopathologic parameters.
Parameter
Overall survival Cancer-speciﬁc survival Biochemical progression free survival
HR 95% CI P value HR 95% CI P value HR 95% CI P value
Pathological stage 0.195 0.052–0.735 0.016 0.00 0.00–9.80 0.923 0.475 0.291–0.775 0.003
Age 1.06 0.977–1.152 0.162 1.068 0.943–1.208 0.29 1.005 0.969–1.043 0.779
Lymph node 0.546 0.158–1.88 0.337 0.832 0.166–4.276 0.823 0.715 0.542–0.943 0.018
Pre operative PSA 1.013 0.982–1.046 0.406 1.007 0.964–1.051 0.766 1.005 0.991–1.019 0.490
Surgical margins 0.878 0.220–3.514 0.855 0.522 0.058–4.686 0.562 0.756 0.440–1.30 0.312
Biopsy Gl. score 1.072 0.600–1.915 0.814 1.093 0.530–2.251 0.81 1.077 0.792–1.466 0.636
Surgery Gl. score 2.82 1.492–5.337 0.001 3.24 1.018–10.311 0.04 2.029 1.461–2.818 0.0001
did not receive adjuvant treatment. Only 5-year BPFS rate
was diﬀerent comparing patients with R0 to those with R1:
62.3% versus 52.5% (log-rank P = 0.023), respectively.
3.5. Postoperative Treatment. Patients with pT3 PCa are gen-
erally considered at risk for disease progression. Therefore,
adjuvant or salvage treatment (RT or ADT) is often applied.
In our study population, additional treatment was given to
32.4% (adjuvant to 15.9% and salvage to 16.5%) of cases:
21.4% in the pT3a and 57.1% in the pT3b subgroups. 20.3%
of patients received ADT, 7.1% RT, and 5% RT with ADT. All
twelve patients with N1 received adjuvant treatment: two of
them received RT with ADT and the other ten ADT alone.
4. Discussion
During the last decade, the discussion about the role
of surgery in locally advanced PCa became increasingly
active. Before that time, treatment of locally advanced PCa
was mostly in hands of radiation oncologists [1]. Such
discussion became possible for several reasons: successful
treatment of high-risk PCa with RT monotherapy requires
high radiation doses (74–80Gy), leading to higher rates of
adverse events. On the other hand, recent studies [2, 9–12]
demonstrate outcomes after surgery which can be compared
with radiation therapy +/− ADT. Our single center study
shows that surgical treatment may indeed be a reasonable
treatment option in locally advanced PCa with 90.7% OS
and 94% CSS at the 5-year follow-up mark. Surgery in pT3a
PCa, independently of cancer diﬀerentiation and PSA level
demonstratedsigniﬁcantlyhigher5-yearOS,CSS,DPFS,and
BPFS rates when compared to pT3b disease (96% versus
72%, 98% versus 77%, 97.3% versus 79.3%, and 60% versus
24.2%, resp.). The survival rates of the pT3a patients in
our study are similar to those reported by Hsu et al. in a
study of 200 patients with unilateral cT3a treated by surgery.
They also showed that progression-free survival rates of
patients with pT3a PCa did not diﬀer signiﬁcantly from
those with pT2 disease [7]. Some other authors have also
reported their outcomes of surgical treatment for T3 PCa.
Summarizing those results, 5-year CSS and OS rates varied
from 85 to 100% and from 75 to 98%, respectively [9–12].
Direct comparison between the outcomes of surgery and
radiation is inadequate because of inherent selection biases,
Gleason score upgrading, or stage migration after surgery.
Nevertheless, this issue could be partially solved using data4 Advances in Urology
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Figure1:TheKaplan-Meieranalysiswithlog-ranktestforoverall(a),cancer-speciﬁcsurvival(b),andbiochemical-progression-freesurvival
(c) stratiﬁed for lymph node status.
from the RTOG trials which compared RT to a combined
approachusingRTandADT[13].InareviewofthoseRTOG
trials, diﬀerent PCa risk groups were identiﬁed with group 2
(Gleason ≤6, T3Nx-N1 or Gleason 7, T1-2Nx) and group 3
(Gleason 7, T3Nx-N1 or Gleason ≥8, T1-2Nx) most closely
corresponding with our study population. After radiation,
the 5-year OS and CSS rates were 82% and 94% for group
2 and 68% and 83% for group 3, respectively [13]. Outcomes
from another long-term study comparing RT to RT with
concomitant ADT were reported by Bolla et al. [14]. In the
EORTC trial, 412 patients with locally advanced PCa were
treated with RT alone or in combination with ADT. Five-
year OS and CSS rates were, respectively, 62 and 79% in
the radiation-alone group. Better survival was reported inAdvances in Urology 5
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Figure2:TheKaplan-Meieranalysiswithlog-ranktestforoverall(a),cancer-speciﬁcsurvival(b),andbiochemical-progression-freesurvival
(c) stratiﬁed for pathological stage.
combination group: 78% and 94%, respectively. Our study
datashowedacomparable94%5-yearCSS,similartoRTand
ADT combination therapy.
ThegroupoflocallyadvancedPCaisheterogeneous.PSA
and specimen Gleason score have a signiﬁcant impact on
the survival analysis. According to our study, pT3a patients
with a PSA <10ng/mL had signiﬁcantly better OS and BPFS
when compared to those with a PSA level >20ng/mL (log
rank P = 0.048 and P = 0.0001, resp.). Patients with a PSA
level of 10 to 20ng/mL did not have signiﬁcantly diﬀerent
OS when compared to PSA <10 or PSA >20ng/mL (log
rank P = 0.552) but had diﬀerent BPFS compared to PSA
>2 0n g / m L( l o gr a n kP = 0.008). In the pT3a group, PSA
had no impact on CSS and DPFS. In the pT3b group, we
found no signiﬁcant impact of PSA level on the 5-year OS,
CSS, or DPFS. A possible explanation for this observation
could be the variable application of adjuvant therapies. 5-
year BPFS rate in the pT3b group was diﬀerent comparing6 Advances in Urology
0
0.2
0.4
0.6
0.8
1
0 20 40 60 80 100
O
v
e
r
a
l
l
s
u
r
v
i
v
a
l
Gleason 6-7 versus Gleason 8–10
P = 0.0001
Followup (months)
Log-rank
(a)
0
0.2
0.4
0.6
0.8
1
0 2 04 06 08 0 1 0 0
Gleason 6-7 versus Gleason 8–10
P = 0.0001
Followup (months)
Log-rank
C
a
n
c
e
r
-
s
p
e
c
i
ﬁ
c
 
s
u
r
v
i
v
a
l
(b)
0
0.2
0.4
0.6
0.8
1
0 2 04 06 08 0 100
Gleason 6-7 versus Gleason 8–10
P = 0.0001
Gleason 6-7
Gleason 8–10
Followup (months)
B
i
o
c
h
e
m
i
c
a
l
-
p
r
o
g
r
e
s
s
i
o
n
-
f
r
e
e
-
s
u
r
v
i
v
a
l
Log-rank
(c)
Figure3:TheKaplan-Meieranalysiswithlog-ranktestforoverall(a),cancer-speciﬁcsurvival(b),andbiochemical-progression-freesurvival
(c) stratiﬁed for Gleason score sum.
patients with PSA >20 to <10ng/mL (log rank P = 0.019).
Some recent studies also studied the role of PSA in survival
and biochemical or disease progression [4, 5, 15]. All authors
agreed that PSA >20ng/mL indeed could be considered as a
high-risk factor. Our ﬁndings support that patients with PSA
>20ng/mL had signiﬁcantly worse BPFS and OS but not CSS
or DPFS rates in pT3 PCa population.
Gleason score has long been recognized as an important
risk indicator for worse outcome. In locally advanced PCa,
biopsy Gleason sum has a tendency to be upgraded, and in
our series upgrading was indeed frequent (up to 50%). In
fact, in our study, specimen Gleason score was identiﬁed as
the most important outcome predictor. Our data showed
a signiﬁcant diﬀerence between survival curves comparing
Gleason score 5–7 to 8–10. More importantly, patients with
postoperative Gleason ≥8 are associated with a 2.8-fold
increased risk of death and 2.4-fold increased risk of disease
progression. If cancer diﬀerentiation after surgery is ≥8, theAdvances in Urology 7
riskofdeathfromcancerincreasesmorethan3-fold.Gleason
score 8–10 is also associated with a higher node-positive rate
when compared with Gleason score 7 (6.3% versus 4.5%,
chi-square test P = 0.03). Most of the published studies
conﬁrm that Gleason score 8–10 indeed determines worse
biochemicalordisease-freesurvival[6,16,17]bothinlocally
advanced and organ-conﬁned disease [18]. Our study shows
that 5-year OS, CSS, DPFS, and BPFS rates in Gleason score
8–10 PCa were 61%, 64%, 62.4%, and 13.5% compared to
96%, 99%, 97.8%, and 56.3% if Gleason score was 5–7.
However, signiﬁcant survival diﬀerences between high- and
moderate-grade PCa do not mean that a more advanced
tumor grade is a contraindication for surgery. Tewari et al.
pointed out that long-term results in high-grade PCa after
surgeryarebetterwhencomparingsurgicallytreatedpatients
with those who underwent RT or conservative treatment
[19]. In 453 patients with biopsy Gleason 8–10, median OS
after surgery was 9.7 years, while for radiation this was 6.7
years and for conservative treatment 5.2 years. The risk of
cancer-related death after surgery was 68% lower than after
conservative treatment and 48% lower than after RT.
The pT3b stage is associated with the poorest oncological
outcomes after surgery. In our study, the rate of positive
margins was 71.7%, while 23.8% and 38.2% had pN1 disease
andspecimenGleasonscore8–10,respectively.Theseadverse
pathological outcomes are directly related to the oncological
outcomes: 5-year CSS was 77%, OS was 72%, DPFS was
79.3%, and BPFS was 24.2%. A subanalysis of T3b patients
without positive lymph nodes (pT3bN0-Nx) showed 5-year
OS, CSS, DPFS, and BPFS rates of 84%, 88%, 94%, and
52.1%, respectively. There are no possibilities to compare the
results of surgery and RT in such small cohort of patients.
If we look to the outcomes (5-year OS rates >75% and CSS
>85%) of radical prostatectomy at advanced stage and high-
grade PCa in large review presented by Van Poppel and
Joniau [2], our pT3b survival data are similar. This suggests
that not all patients with cancer extending into the seminal
vesicles are destined to have poor outcomes. Lymph node
status and Gleason score seem to play the most important
role in pT3b PCa outcomes.
From our analysis the presence of positive surgical
margins was not signiﬁcant predictor for survival in Cox
regression. The Kaplan-Meier analysis showed that only
5-year BPFS was diﬀerent comparing R0 to R1 in all
study cohort (55.9% versus 44.2%, log rank P = 0.08).
We found similar data excluding patients who received
adjuvant treatment. Only BPFS was diﬀerent comparing
surgical margin status. The similar ﬁndings were reported
by Hsu et al. [7]. Authors concluded that margin status
was a signiﬁcant independent predictor in BPFS but did
not inﬂuence OS, CSS, and DPFS. The question remains
if patients with positive margins should receive adjuvant
treatmentinpT3cases.OurstudydataconﬁrmsthatR1with
Gleason ≥8 is proper candidate for adjuvant treatment, but
more randomized studies are needed to cover this topic.
Generally, it is accepted that patients with locally
advanced PCa at ﬁnal histology are ideal candidates for
additional treatment after surgery. Up until now, there is
still no consensus on which treatment modality—RT, ADT,
or a combination—is the best choice to decrease the risk of
disease progression following surgery. In the present study,
only 32.4% of cases (21.4% in pT3a and 57.1% in pT3b)
received additional treatment: 15.9 received adjuvant and
16.5% salvage treatment. Cox regression analysis did not
show impact of adjuvant therapy on survival, but we were
unable to investigate real inﬂuence of adjuvant treatment
on outcomes because of small number of cases and not
randomized study design. According to our data, 42.9% of
patients in pT3b and 78.6% in pT3a did not receive any
additional treatment during median 4.5-year followup. It
shows that surgery as monotherapy could be discussed with
p a t i e n te v e ni ns u s p e c t e dT 3P C a .
With 5-year OS, CSS, DPFS, and BPFS of 91%, 94%,
91.8%,and48.4%,ourstudysupportsthenotionthatradical
prostatectomy with adjuvant or salvage therapy as RT plus
ADT when needed may provide comparable outcomes in
locally advanced PCa, especially in pT3a. However, this ﬁnd-
ing should be conﬁrmed in prospective, randomized studies.
5. Conclusions
Radical prostatectomy may oﬀer very good CSS, OS, DPFS,
and BPFS rates in pT3a PCa. However, outcomes in patients
with pT3b or specimen Gleason ≥8 were signiﬁcantly worse,
suggesting the need for multimodality treatment in those
cases.
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